Why timing matters before any injection is considered

For many people researching knee injections, the first practical question is not 'which injection?' but 'is it even the right time?' That question has a clear clinical answer, and understanding it makes every subsequent suitability decision easier to follow.

Intra-articular injection sits in the second tier of knee osteoarthritis management. Before a clinician will consider one, they need reasonable confidence that first-line care has been given a genuine trial — not bypassed. That first line consists of structured exercise therapy, weight management where relevant, and physiotherapy aimed at strengthening the muscles that support the joint. These are not formalities. Evidence consistently shows they reduce pain and improve function in mild-to-moderate knee OA, and the 2026 multidisciplinary glucocorticoid consensus positions injection as appropriate only once this non-pharmacological phase has proved insufficient.

Oral analgesia — paracetamol, topical anti-inflammatories, or oral NSAIDs — is the next step before an injection is considered. If these have been tried at an adequate dose and duration and the pain persists, the clinical picture changes meaningfully.

Once both those stages have been worked through, intra-articular injection occupies a specific place: it is, as Ayhan et al. (2014) describe in a widely cited review, the last non-operative modality — the bridge between conservative management and surgical assessment. That framing is useful because it explains why clinicians are deliberate about timing rather than dismissive about injections.

If exercise, physiotherapy, and oral analgesia have already been tried and found inadequate, that prior effort is precisely what moves a patient into the group for whom injection suitability becomes a meaningful question to explore.

What your X-ray grade means for injection response

Radiographic severity — typically reported as a Kellgren-Lawrence (KL) grade on a scale of I to IV — is one of the most practical structural filters a clinician uses when weighing injection suitability.

Grades II and III represent the range where injections tend to work best. At this stage there is meaningful cartilage loss and joint-space narrowing — enough to generate persistent symptoms — but sufficient cartilage and joint space remain to lubricate and support. Viscosupplementation with hyaluronic acid, for example, depends on having a viable joint environment; systematic review evidence confirms that excluding grade IV patients from HA trials materially improves pooled outcomes, indicating that end-stage disease blunts the response. The large RESTORE randomised trial, which tested PRP in 288 patients with symptomatic medial knee OA, similarly enrolled only those with KL grade 2 or 3 aged 50 and over — outside those boundaries the evidence base thins considerably.

KL grade IV, often described informally as 'bone-on-bone', shifts the clinical conversation rather than ending it. Viscosupplementation becomes difficult to justify at this stage; the conversation moves toward corticosteroid injections for symptom relief or, more often, toward surgical assessment.

Importantly, a KL grade is one input into the suitability picture, not a verdict. Symptoms, function, activity goals, and the degree of daily disruption all weigh alongside structural severity. A patient should not attempt to self-interpret their grade from a scan report — that grading only becomes meaningful when a clinician sets it alongside the full clinical picture.

How your symptom pattern shapes the injection choice

Assuming the earlier checkpoints have been met — adequate prior conservative care and an X-ray grade that supports injection — the next clinical question shifts from whether to inject to what. Here, the character of the patient's symptoms does most of the work.

The key distinction is between inflammatory and mechanical pain. An inflammatory flare presents with visible or palpable swelling, warmth around the joint, and pain that is typically severe — a visual analogue scale score of 7 or above is one commonly used threshold. When symptoms follow this pattern, or when the patient cannot tolerate NSAIDs, a corticosteroid (glucocorticoid) injection is the preferred choice. The 2026 multidisciplinary glucocorticoid consensus — a 22-recommendation expert document specifically addressing knee OA — explicitly identifies this scenario as the target indication for GC injection, noting its fast onset and capacity to reduce intra-articular inflammation directly.

Chronic, stable pain that is more of a dull ache than an acute flare tells a different story. Without active effusion or significant swelling, the joint environment is better suited to hyaluronic acid viscosupplementation, which works by restoring lubrication and cushioning rather than suppressing inflammation. In this phenotype, HA may provide meaningful symptom relief for up to six months.

PRP occupies a similar non-inflammatory space — it is generally considered where biological tissue support is the goal, within the KL grade 2–3 window, though the RESTORE trial found no clinically significant benefit over placebo at 12 months, meaning its place in practice remains under review.

Arthrosamid, a polyacrylamide hydrogel, does not compete with any of the above at first presentation. It is a step-up option for patients who have already tried and not benefited sufficiently from corticosteroid and HA injections.

None of this means a patient can — or should — map their own symptoms to an injection type. Recognising a pattern is useful context for a consultation; the actual selection involves weighing contraindications, structural findings, and treatment history together, and that is a clinical decision made with a specialist.

Absolute and relative contraindications to know about

Before any injection proceeds, a clinician will run through a short but important screening step — not to exclude patients unnecessarily, but to make sure the timing and type of injection are safe. Knowing what is being screened for helps patients come to that conversation prepared.

Active infection is the one absolute rule. An active local skin infection, soft-tissue compromise at the injection site, systemic infection, or suspected septic arthritis makes any intra-articular injection unsafe until the infection has fully resolved. There are no exceptions here, and this applies to every injection type.

Several factors require discussion rather than automatic exclusion:

• Coagulopathy or anticoagulant therapy — the bleeding risk is manageable for simpler injections but more relevant for biologic and hydrogel options such as PRP or Arthrosamid, which clinicians will weigh carefully.
• Uncontrolled systemic illness — poorly managed diabetes or similar conditions affect healing and infection risk; the situation may not be a permanent barrier, but it needs to be stable first.
• Hypersensitivity to injectate components — relevant for avian-derived hyaluronic acid preparations, polyacrylamide, or other specific agents.
• Significant varus or valgus deformity — structural malalignment does not make injection impossible, but evidence suggests it reduces the likelihood of a sustained response, so the clinical discussion should address realistic expectations.

Planned knee replacement surgery is a specific timing consideration. Around 30% of patients receive a corticosteroid injection before total knee arthroplasty (TKA), and the evidence is clear that as the gap between injection and surgery shortens, periprosthetic infection risk rises. When the interval exceeds six to seven months, no elevated risk has been observed. Patients who are on a surgical pathway, or who think surgery may be on the horizon, should flag this with the assessing clinician before any corticosteroid injection is arranged.

Why outcomes vary and what the evidence actually says

The statistics are worth understanding clearly — not to discourage, but to explain why the multi-dimensional framework described in earlier sections exists at all. Research involving 330 knee OA patients found that only 25.5% achieved significant pain improvement from corticosteroid injection, measured on the WOMAC scale. That means for most patients it does not produce a meaningful result, even when the clinical rationale is sound. A 2025 review in JBJS reached a parallel conclusion about hyaluronic acid, advising against routine use across the board and endorsing instead a conditional, case-by-case approach based on individual patient profile.

This variability is not random — certain factors consistently shift the odds. BMI appears to matter for PRP specifically: in one published study, non-obese patients (BMI under 30) showed meaningfully better WOMAC outcomes at longer-term follow-up compared with those classified as obese, who also carried a higher likelihood of eventually needing arthroplasty. Early evidence from hydrogel injection data suggests that bilateral knee symptoms may be a relevant factor in identifying who benefits most, though this remains a developing picture rather than a settled finding.

For newer biologic treatments — including bone marrow aspirate concentrate, stromal vascular fraction, and stem-cell-derived injections — the suitability evidence is thinner still, and current literature does not support their routine use.

No widely validated patient-facing tool yet consolidates these variables into a single eligibility score. A structured clinical assessment — weighing imaging, symptom phenotype, treatment history, BMI, and comorbidities together — remains the only reliable way to work through the uncertainty responsibly.

What a suitability assessment actually involves

A structured suitability consultation covers three areas in sequence: clinical history, physical examination, and a review of existing imaging.

The history focuses on symptom duration, which treatments have been tried and for how long, current medications, and any planned surgery. The examination looks at joint-line tenderness, the presence or absence of effusion, range of motion, and structural alignment. If no recent imaging is available, the clinician may request X-rays or an MRI before making a recommendation — that is part of appropriate suitability screening, not a delay.

Patients who come prepared tend to get more from the consultation. Bringing a list of previous treatments (with approximate dates), current medications, and any prior scan reports allows the clinician to avoid repeating what has already been tried and to place the current symptoms in full context.

The outcome of that assessment is not always a referral for injection. It may be a recommendation to continue or modify conservative care, or a surgical opinion if the clinical picture suggests the window for injection has passed.

The framework traced across this article — treatment-step readiness, radiographic grade, symptom phenotype, contraindication screening, and individual modifiers such as BMI — is precisely what a specialist works through in that room. Realistic candidates are those whose conservative care has been genuinely exhausted, whose structural severity falls in the mild-to-moderate range, and who carry no absolute contraindications. Patients still early in their treatment pathway, or with end-stage joint disease, are unlikely to benefit from injection alone and would typically be directed toward a different approach.

For anyone ready to explore where they sit in that picture, the AMSK suitability assessment at amsk.co.uk applies the same framework — not a simple yes or no, but a structured conversation about the full clinical picture.

1. [1] Expert consensus on glucocorticoids injection for knee osteoarthritis. (2026). https://doi.org/10.1186/s13018-025-06363-1 https://doi.org/10.1186/s13018-025-06363-1
2. [2] Machine learning for patient selection in corticosteroid decision making in knee osteoarthritis: A feasibility model. (2025). https://doi.org/10.5662/wjm.v15.i4.105493 https://doi.org/10.5662/wjm.v15.i4.105493
3. [3] Effect of Intra-articular PRP vs Placebo (RESTORE RCT) – JAMA 2021. (2021). https://doi.org/10.1001/jama.2021.19415 https://doi.org/10.1001/jama.2021.19415
4. [4] Injection-Based Therapies for the Management of Hip and Knee Osteoarthritis – JBJS 2025. (2025). https://doi.org/10.2106/JBJS.25.00239 https://doi.org/10.2106/JBJS.25.00239
5. [5] PRP Injection Efficacy in Obese vs Non-Obese Patients with Knee OA – JCM 2024. (2024). https://doi.org/10.3390/jcm13092590 https://doi.org/10.3390/jcm13092590